Business
VALEO PHARMA ANNOUNCES LISTING TO THE TORONTO STOCK EXCHANGE
VALEO PHARMA ANNOUNCES LISTING TO THE TORONTO STOCK EXCHANGE.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA ANNOUNCES LISTING TO THE TORONTO STOCK EXCHANGE\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA ANNOUNCES LISTING TO THE TORONTO STOCK EXCHANGE\nCanada NewsWire\nMONTREAL, March 28, 2022\n\n\n\nThe Company's shares and warrants to start trading on March 29th, 2022 MONTREAL, March 28, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, announced today that it has received final approval for the listing of its common shares and warrants on the Toronto Stock Exchange (\"TSX\").\n\n \n \n \n \n \n \n\n \nThe Company's common shares and warrants will commence trading on the TSX effective as of market open on Tuesday March 29, 2022 (the \"Effective Date\"), and will continue to trade under the current symbols of \"VPH\", \"VPH.WT\" and \"VPH.WT.A. The Company's commons shares and warrants will concurrently be de-listed from the CSE as of the Effective Date.\n\"Listing on the TSX, Canada's senior stock exchange, is an important step supporting our development as a leading Canadian pharmaceutical company\", said Steve Saviuk, CEO. \"The TSX platform  enhances Valeo's exposure to a broader investor audience which will benefit all our shareholders\".\nAbout Valeo Pharma \nValeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology, Neurodegenerative Diseases, Oncology and other specialty products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.\nForward Looking Statements\n This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are \"forward-looking\" because they are based on our current expectations about the marke...